Results 311 to 320 of about 406,491 (336)

Immunotherapy in triple-negative breast cancer

Medical Oncology, 2017
Breast cancer can be classified based on the expression or lack of expression of protein receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (Her2). The basal molecular subtype is mostly made up of breast cancers that do not express ER/PR or Her2, triple-negative breast cancers (TNBC) (Bertucci ...
Heather Katz, Mohamed Alsharedi
openaire   +2 more sources

Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.

Cancer Cell
Strategies are needed to better identify patients that will benefit from immunotherapy alone or who may require additional therapies like chemotherapy or radiotherapy to overcome resistance.
S. Shiao, Kenneth H. Gouin, Nathan Ing, Alice Ho, R. Basho, Aagam Shah, Richard H Mebane, David Zitser, Andrew Martinez, Natalie-Ya Mevises, Bassem Ben-Cheikh, Regina M. Henson, M. Mita, P. McAndrew, S. Karlan, Armando E Giuliano, A. Chung, F. Amersi, C. Dang, Heather Richardson, W. Shon, F. Dadmanesh, M. Burnison, Amin Mirhadi, Z. Zumsteg, R. Choi, M. Davis, Joseph Lee, D. Rollins, Cynthia Martin, N. H. Khameneh, Heather McArthur, S. R. Knott   +32 more
semanticscholar   +1 more source

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Journal of the American Medical Association (JAMA)
Importance The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant ...
R. Leon-Ferre, S. Jonas, R. Salgado, S. Loi, V. D. de Jong, Jodi M. Carter, T. Nielsen, S. Leung, N. Riaz, Stephen K. L. Chia, G. Jules-Clement, G. Curigliano, C. Criscitiello, V. Cockenpot, M. Lambertini, Vera J. Suman, B. Linderholm, John W M Martens, C. V. van Deurzen, A. M. Timmermans, T. Shimoi, S. Yazaki, M. Yoshida, Sung-Bae Kim, H. Lee, M. Dieci, Guillaume Bataillon, A. Vincent‐Salomon, Fabrice André, M. Kok, Sabine C. Linn, M. Goetz, S. Michiels   +32 more
semanticscholar   +1 more source

Triple-negative breast cancers

Expert Review of Anticancer Therapy, 2023
Steven A, Narod, Rebecca, Dent
openaire   +2 more sources

Advanced Triple-Negative Breast Cancer

Seminars in Oncology Nursing
Our focus within this review is to summarize key advances and new therapeutic approaches within advanced triple-negative breast cancer. In addition, we highlight the importance of multidisciplinary management, discussing key issues for patients and importance of the supportive role that specialist nurses provide.Peer-reviewed literature, clinical ...
Patel, G, Prince, A, Harries, M
openaire   +3 more sources

Immunohistochemistry for Triple-Negative Breast Cancer

2016
Triple-negative breast cancers are a heterogeneous group of tumors that are, as yet, not entirely understood. Although triple-negative carcinomas are strictly defined as invasive carcinomas lacking expression of estrogen receptor, progesterone receptor, and HER2, some use the terms triple-negative and basal-like cancer synonymously.
Naidoo, Kalnisha, Pinder, Sarah E
openaire   +3 more sources

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

Nature Reviews Clinical Oncology, 2021
G. Bianchini, C. De Angelis, L. Licata, L. Gianni   +3 more
semanticscholar   +1 more source

Pembrolizumab in Triple-Negative Breast Cancer

New England Journal of Medicine, 2022
Ryan, Sun, Lee-Jen, Wei
openaire   +3 more sources

Triple-Negative Breast Cancer

2019
Triple-negative breast cancer (TNBC) represents approximately 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2). The annual incidence of TNBC is estimated to be approximately 40,000, with 20,000 diagnosed with metastatic ...
Ritika Vankina, Yuan Yuan
openaire   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Özge Gumusay, Hope S Rugo   +2 more
exaly